Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs
Konstantin Byrgazov, Marianne Kraus, Andrej Bešše, Ana Slipicevic, Fredrik Lehmann, Christoph Driessen, Lenka Bešše
Abstract
• High ABCB1 expression still predicts shorter survival in myeloma. • ABCB1 expression is elevated in myeloma progressing to extramedullary disease. • Melflufen and bortezomib are the most promising in ABCB1-positive high risk myeloma.
Topics & Concepts
CarfilzomibMultiple myelomaBortezomibMyeloma proteinCancer researchMedicineMultiple drug resistanceProteasome inhibitorDrug resistanceOncologyImmunologyBiologyGeneticsDrug Transport and Resistance MechanismsMultiple Myeloma Research and TreatmentsCancer therapeutics and mechanisms